Eton Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-13.
0001437749-26-027684
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-05.
0001710340-26-000009
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 11 previous paragraphs and 3 current paragraphs.
3 unchanged; 0 reworded; 0 added; 8 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Removed paragraphs (8)
Previous report
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Previous report
During the quarter ended June 30, 2026, the Company issued an aggregate of 296,215 shares of its common stock at a weighted average exercise price of $31.83 through the exercise of warrants. The warrants were exercised on a cashless exercise basis and as a result, no cash proceeds were received by the Company and 62,901 warrants were surrendered. The warrants exercised were originally issued in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended Securities Exchange Act of 1933 (the “Securities Act”), and the shares of common stock issued upon exercise of the warrants were issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act. The issuance was made without general solicitation or advertising, and the investor represented that they were acquiring the securities for investment purposes and not with a view to distribution.
Previous report
Item 3. Defaults Upon Senior Securities
Previous report
Rule10b*-5(1) Trading Plans.* During thethree-month period ended* June 30, 2026*, no director or officer of the Company adopted or terminated a “Rule10b5-1 trading arrangement” or “non-Rule10b5-1 trading arrangement,” as each term is defined in Item408(a) of Regulation S-K.